DHFR and cancer: Compounds I, II, and III (Figure 1) were the most active and had similar activity to another DHFR inhibitor, methotrexate (IC50 = 0.08 μM), a potent and widely used anticancer agent usually included in therapeutic protocols for many different cancers.